← 홈

PD-1 / PD-L1

65개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 65개
AntibodySHOTFDACuratedFDABiologicMerckvedotin plus pembrolizumab …Approved

pembrolizumab (Keytruda)

Multiple solid tumors · PD-1

#PD-1#Antibody#Approved#FDA승인#바이오정보모아추천+5
효능 ORR 100%임상시험 1620상태 APPROVED
AntibodyBHotstaleMerckPhase 2

pembrolizumab or nivolumab (The combination of radiotherapy with anti-PD1, The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab))

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#인기#항체+3
효능 ORR 56.1%임상시험 110상태 ACTIVE
AntibodyAstaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody)

Triple-Negative Breast Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#인기#항체+4
효능 ORR 76.7%임상시험 90상태 ACTIVE
AntibodyAstaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody)

Carcinoma, Non-Squamous Non-Small Cell Lung · PD-L1

#PD-L1#Antibody#Phase3#인기#항체+5
효능 ORR 76.7%임상시험 88상태 ACTIVE
AntibodystaleRochegovitecan in patients with …Phase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody)

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase3#인기#항체+4
효능 ORR 75%임상시험 61상태 ACTIVE
ADCBiologicMerckVedotin ± Pe…Phase 2

nivolumab OR pembrolizumab (glembatumumab vedotin and PD-1 targeted checkpoint inhibitor, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab))

Melanoma · PD-1

#PD-1#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 50%임상시험 60상태 DISCONTINUED
ADCBiologicAtreca, Inc.vedotin (BV), an anti-CD30 …Preclinical

PD-1 and PD-L1 inhibitor (PD-1 and PD-L1 inhibitor)

Immune-related Adverse Event; Malignant Solid Tumors · PD-1

#PD-1#ADC#Preclinical#인기#항체약물접합체+5
효능 ORR 59%임상시험 59상태 RECRUITING
AntibodystaleJunshi BiosciencesPhase 2

humanized anti-PD-1 monoclonal antibody toripalimab (humanized anti-PD-1 monoclonal antibody toripalimab)

Advanced Melanoma; Metastatic Melanoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 30상태 ACTIVE
AntibodystaleAkesoPhase 2

Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） (Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）)

Bladder Cancer; Muscle-invasive Bladder Cancer · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 16상태 RECRUITING
AntibodystaleBeiGenePhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48 Combined With Tislelizumab)

Upper Tract Urothelial Carcinoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+3
임상시험 12상태 RECRUITING
CGTBiologicstaleTILT Biotherapeutics Ltd.Phase 1

Oncolytic virus Plus Anti-PD1 and Chemotherapy (Oncolytic virus Plus Anti-PD1 and Chemotherapy)

Pancreatic Cancer · Pancreatic Cancer

#PancreaticCancer#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 8상태 RECRUITING
CGTBiologicstaleAllife Medical Science and Tech…Phase 1

pd-1 and DC-NK cells (pd-1 and DC-NK cells)

Solid Tumor · PD-1

#PD-1#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 4상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody)

Breast Neoplasms · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+3
효능 ORR 20%임상시험 3상태 ACTIVE
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin, anti-PD-1 antibody.)

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma · PD-1

#PD-1#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 RECRUITING
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy)

Gastric Cancer · PD-1

#PD-1#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 ACTIVE
AntibodyBiologicstaleShanghai Kechow Pharma, Inc.Phase 2

Tunlametinib+PD-1 mAb (Tunlametinib+PD-1 mAb)

Gastric Adenocarcinoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+3
임상시험 2상태 RECRUITING
CGTBiologicstaleShanghai Cell Therapy Group Co.…Phase 1

αPD1-MSLN-CAR T cells (αPD1-MSLN-CAR T cells)

Colorectal Cancer; Ovarian Cancer · Non-small-cell Lung Cancer

#Non-small-cellLungCancer#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 2상태 ACTIVE
CGTBiologicstaleGuangzhou Anjie Biomedical Tech…Phase 2

AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells (AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells)

Advanced Breast Cancer; Breast Neoplasm Malignant Female · PD-1

#PD-1#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleShanghai Cell Therapy Research …Phase 2

Anti-CTLA-4/PD-1 expressing MUC1-CAR-T (Anti-CTLA-4/PD-1 expressing MUC1-CAR-T)

Advanced Solid Tumor · PD-1

#PD-1#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Anti-PD-1 Antibody Plus Chidamide and Rituximab (Anti-PD-1 Antibody Plus Chidamide and Rituximab)

Relapsed or Refractory DLBCL · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE

1 / 4 페이지

← 이전다음 →